Stokes WA, Molina E, McDermott JD, et al. - Researchers conducted the study for analyzing the effect of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) in head and neck cancer (HNC). The Surveillance, Epidemiology, and End Results-Medicare linked dataset yielded almost 5,000 patients who were characterized by ACEi and ARB, as well as diagnoses of chronic kidney disease (CKD) or hypertension (HTN). ARB use has been linked to better overall survival and cancer-specific survival in HNC patients with CKD or HTN.